Zacks Investment Research downgraded shares of OncoCyte (NYSEAMERICAN:OCX) from a buy rating to a hold rating in a report published on Tuesday.

According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “

Separately, ValuEngine cut OncoCyte from a hold rating to a sell rating in a research note on Thursday, October 5th.

Shares of OncoCyte (OCX) traded up $0.05 on Tuesday, reaching $4.30. The company had a trading volume of 7,170 shares, compared to its average volume of 30,713. The stock has a market cap of $135.14 and a PE ratio of -6.94. OncoCyte has a 1 year low of $3.60 and a 1 year high of $7.85.

An institutional investor recently raised its position in OncoCyte stock. Broadwood Capital Inc. raised its holdings in shares of OncoCyte Co. (NYSEAMERICAN:OCX) by 17.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,596,680 shares of the biotechnology company’s stock after acquiring an additional 540,000 shares during the quarter. OncoCyte makes up 4.5% of Broadwood Capital Inc.’s investment portfolio, making the stock its 5th largest holding. Broadwood Capital Inc. owned 11.48% of OncoCyte worth $27,155,000 as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at

OncoCyte Company Profile

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Get a free copy of the Zacks research report on OncoCyte (OCX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with's FREE daily email newsletter.